Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
IPO Year:
Exchange: NASDAQ
Website: https://www.alaunos.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2022 | $3.00 | Overweight | Wells Fargo |
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
Wells Fargo resumed coverage of Alaunos Therapeutics with a rating of Overweight and set a new price target of $3.00
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quarter of 2024 HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Compan
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced financial results for the second quarter ended June 30, 2023. The Company also announced a strategic repriori
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company's TCR-T therapy in solid tumors targeting specific, cancer-driving mutations currently being evaluated in a Phase 1/2 open-label, dose-escalation trial at The University of Texas MD Anderson Cancer Center. Details of th
TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indicationsTreatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-upProof-of-concept demonstrated for non-viral Sleeping Beauty cell engineering platform in effective manufacturing of TCR-T cell therapies with all products achieving >90% TCR positivityData to be presented on Saturday, June 3, at 8:00 a.m. CT HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASD
Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company's focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ET HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announce
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To partici
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead non-viral Sleeping Beauty TCR-T cell therapy program in solid tumors at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago. The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation trial being conducted at The University of Texas MD Anderson Cancer Center. The trial is enrolling patients with non-
HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company's Board of Directors, effective immediately. Dr. Hofmeister will replace Chris Bowden, MD. "We extend our gratitude to Chris for his invaluable contributions to Alaunos during his tenure, and welcome Robert to the Alaunos Board," said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "Robert bring
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences. Cantor's The Future of Oncology Virtual SymposiumDate: Tuesday, April 4, 2023 Format: Fireside Chat and 1x1 MeetingsLocation: Virtual 22nd Annual Needham Virtual Healthcare ConferenceDate: Monday, April 17, 2023Format: Company Presentation and 1x1 Meetings Location: Virtual A live webcast of the Needham presentation will be accessible on the Com
Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T effortsAdvancing TCR-T Library Program towards Phase 2 readiness with accelerated patient enrollment following proof-of-concept of Sleeping Beauty TCR-T in solid tumors targeting driver mutationsExpanded TCR library with two new TCRs; expect to increase to 15 TCRs using hunTR® TCR discovery platform in 2023Executing against multi-pronged manufacturing strategy; completed transition from fresh to cryopreserved cell product to increase treatment flexibility and reduce manufacturing process timeCompany to h
Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company's focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ET HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announce
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To partici
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at
Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON)Actively enrolling patients in TCR-T Library Phase 1/2 trial at the second dose level; expect to treat next patient in 4Q22Expanded manufacturing capacity to produce two products simultaneouslyExpect to file Investigational New Drug (IND) amendment in 4Q22 to add two additional TCRs to TCR library and move from a fresh to cryopreserved manufacturing process, reducing manufacturing time by 13%Company to host conference call today at 8:30 AM ET HOUSTON, Nov. 14, 2022 (
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will recei
Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific conference; moving ahead with second dose levelExtended Cooperative Research and Development Agreement for development of personalized TCR-T cell therapies with the National Cancer Institute of the National Institute of Health to 2025Appointed Abhishek Srivastava, Ph.D. as VP, Technical OperationsAdvancing multi-pronged strategy to bolster in-house manufacturing capacityOperating cash burn in 2Q 2022 was $8.2 million, a decrease of 62% from the same period last year HOUSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Alaunos Thera
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced that it will report financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a c
Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications Will present preclinical data today at the ASGCT 25th Annual Meeting highlighting the potential of mbIL-15 as a potent and more durable TCR-T cell therapy Will present a trial in progress poster for the TCR-T Library Phase 1/2 trial at the 2022 ASCO Annual Meeting being held from June 2-6, 2022, in Chicago, IL HOUSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the first quarter ended March 31, 20
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results. The conference call can be accessed by dialing 844-309-0618 (United States) or 661-378-9465 (International) with the conference code 2495623. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Alaunos website at www.alauno
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and is expected to dose in 2Q 2022Extended CRADA with the National Cancer Institute focused on evaluating Alaunos' TCR-T Library in a personalized TCR-T programThe Company has successfully identified proprietary TCRs under the hunTR™ platform HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the fourth quarter and full year ended December 31, 2021. "Over the course of 2021 we successfully restructured
SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)
SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)
SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)
SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)
SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)
SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)
SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)
SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)
SC 13G - Alaunos Therapeutics, Inc. (0001107421) (Subject)
SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)
PRE 14A - Alaunos Therapeutics, Inc. (0001107421) (Filer)
10-K/A - Alaunos Therapeutics, Inc. (0001107421) (Filer)
8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
10-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
10-Q - Alaunos Therapeutics, Inc. (0001107421) (Filer)
8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
10-Q - Alaunos Therapeutics, Inc. (0001107421) (Filer)
8-K/A - Alaunos Therapeutics, Inc. (0001107421) (Filer)
HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company's Board of Directors, effective immediately. Dr. Hofmeister will replace Chris Bowden, MD. "We extend our gratitude to Chris for his invaluable contributions to Alaunos during his tenure, and welcome Robert to the Alaunos Board," said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "Robert bring
HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations. Dr. Srivastava will lead the Company's manufacturing operations, including overseeing process optimization and capacity expansion. "Abhi brings extensive experience in cell therapy technical operations, and I am pleased to welcome him to our team," commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "He joins Alaunos at an exciting time as we continue to advance development of our promising TCR T Library
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,